Skip to main content Accessibility help
Hostname: page-component-65dc7cd545-nrv4r Total loading time: 0.261 Render date: 2021-07-25T00:22:25.056Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Vitamin D deficiency, behavioral atypicality, anxiety and depression in children with chromosome 22q11.2 deletion syndrome

Published online by Cambridge University Press:  28 July 2016

L. Kelley
Department of Psychology, University of New Orleans, New Orleans, LA, USA
A. F. P. Sanders
Department of Psychology, University of New Orleans, New Orleans, LA, USA
E. A. Beaton
Department of Psychology, University of New Orleans, New Orleans, LA, USA
E-mail address:


Chromosome 22q11.2 deletion syndrome (22q11.2DS) is a complex developmental disorder with serious medical, cognitive and emotional symptoms across the lifespan. This genetic deletion also imparts a lifetime risk for developing schizophrenia that is 25–30 times that of the general population. The origin of this risk is multifactorial and may include dysregulation of the stress response and immunological systems in relation to brain development. Vitamin D is involved in brain development and neuroprotection, gene transcription, immunological regulation and influences neuronal signal transduction. Low levels of vitamin D are associated with schizophrenia, depression and anxiety in the general population. Yet, little is known about how vitamin D levels in children with 22q11.2DS could mediate risk of psychosis in adulthood. Blood plasma levels of vitamin D were measured in children aged 7–16 years with (n=11) and without (n=16) 22q11.2DS in relation to parent reports of children’s anxiety and atypicality. Anxiety and atypicality in childhood are risk indicators for the development of schizophrenia in those with 22q11.2DS and the general population. Children with 22q11.2DS had lower vitamin D levels, as well as elevated anxiety and atypicality compared with typical peers. Higher levels of anxiety, depression and internalizing problems but not atypicality were associated with lower levels of vitamin D. Vitamin D insufficiency may relate to higher levels of anxiety and depression, in turn contributing to the elevated risk of psychosis in this population. Further study is required to determine casual linkages between anxiety, stress, mood and vitamin D in children with 22q11.2DS.

Original Article
© Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2016 

Access options

Get access to the full version of this content by using one of the access options below.


1. Karayiorgou, M, Simon, TJ, Gogos, JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci. 2010; 11, 402416.CrossRefGoogle Scholar
2. Shprintzen, RJ, Higgins, AM, Antshel, K, et al. Velo-cardio-facial syndrome. Curr Opin Pediatr. 2005; 17, 725730.CrossRefGoogle ScholarPubMed
3. Tang, SX, Yi, JJ, Calkins, ME, et al. Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated. Psychol Med. 2014; 44, 12671277.CrossRefGoogle ScholarPubMed
4. Beaton, EA, Simon, TJ.. How might stress contribute to increased risk for schizophrenia in children with chromosome 22q11.2 deletion syndrome? J Neurodev Disord. 2011; 3, 6875.CrossRefGoogle ScholarPubMed
5. Gothelf, D, Gruber, R, Presburger, G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry. 2003; 64, 11631169.CrossRefGoogle Scholar
6. Sobin, C, Kiley-Brabeck, K, Karayiorgou, M. Associations between prepulse inhibition and executive visual attention in children with the 22q11 deletion syndrome. Mol Psychiatry. 2005; 10, 553562.CrossRefGoogle ScholarPubMed
7. Antshel, KM, Shprintzen, R, Fremont, W, et al. Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2010; 49, 333344.Google ScholarPubMed
8. Swillen, A, Vandeputte, L, Cracco, J, et al. Neuropsychological, learning and psychosocial profile of primary school aged children with the velo-cardio-facial syndrome (22q11 deletion): evidence for a nonverbal learning disability? Child Neuropsychol. 1999; 5, 230241.Google ScholarPubMed
9. Angkustsiri, K, Leckliter, I, Tartaglia, N, et al. An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11. 2 deletion syndrome. J Dev Behav Pediatr. 2012; 33, 713720.CrossRefGoogle ScholarPubMed
10. Fung, WLA, McEvilly, R, Fong, J, et al. Elevated prevalence of generalized anxiety disorder in adults with 22q11.2 deletion syndrome. Am J Psychiatry. 2010; 167, 998.CrossRefGoogle ScholarPubMed
11. Niarchou, M, Zammit, S, van Goozen, SH, et al. Psychopathology and cognition in children with 22q11. 2 deletion syndrome. Br J Psychiatry. 2014; 204, 4654.CrossRefGoogle ScholarPubMed
12. Stephenson, DD, Beaton, EA, Weems, CF, Angkustsiri, K, Simon, TJ. Identifying patterns of anxiety and depression in children with chromosome 22q11. 2 deletion syndrome: comorbidity predicts behavioural difficulties and impaired functional communications. Behav Brain Res. 2014; 276, 190198.CrossRefGoogle ScholarPubMed
13. Schneider, M, Van der Linden, M, Menghetti, S, et al. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome. J Psychiatr Res. 2014; 48, 8693.CrossRefGoogle ScholarPubMed
14. Gothelf, D, Feinstein, C, Thompson, T, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry. 2007; 164, 663669.CrossRefGoogle ScholarPubMed
15. Gothelf, D, Schneider, M, Green, T, et al. Risk factors and the evolution of psychosis in 22q11. 2 deletion syndrome: a longitudinal 2-site study. J Am Acad Child Adolesc Psychiatry. 2013; 52, 11921203, e1193.CrossRefGoogle ScholarPubMed
16. Grober, U, Spitz, J, Reichrath, J, Kisters, K, Holick, M. Vitamin D: update 2013: from rickets prophylaxis to general preventive healthcare. Dermatoendocrinol. 2013; 5, 331347.CrossRefGoogle ScholarPubMed
17. Willis, KS, Smith, DT, Broughton, KS, Larson-Meyer, DE. Vitamin D status and biomarkers of inflammation in runners. Open Access J Sports Med. 2012; 3, 3542.Google ScholarPubMed
18. Pojednic, RM, Ceglia, L, Lichtenstein, AH, Dawson-Hughes, B, Fielding, RA. Vitamin D receptor protein is associated with interleukin-6 in human skeletal muscle. Endocrine. 2014; 49, 512520.CrossRefGoogle ScholarPubMed
19. Pojednic, RM, Ceglia, L, Olsson, K, et al. Effects of 1, 25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin D receptor in human skeletal muscle cells. Calcif Tissue Int. 2015; 96, 256263.CrossRefGoogle ScholarPubMed
20. Muscogiuri, G, Palomba, S, Caggiano, M, et al. Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. Endocrine. 2015; 53, 538542.CrossRefGoogle ScholarPubMed
21. Adorini, L, Penna, G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008; 4, 404412.CrossRefGoogle ScholarPubMed
22. Holick, MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004; 80, 1678S1688S.Google ScholarPubMed
23. Cieslak, K, Feingold, J, Antonius, D, et al. Low vitamin D levels predict clinical features of schizophrenia. Schizophr Res. 2014; 159, 543545.CrossRefGoogle ScholarPubMed
24. Graham, KA, Keefe, RS, Lieberman, JA, et al. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv Psychiatry. 2014; 9, 397405.CrossRefGoogle ScholarPubMed
25. Itzhaky, D, Amital, D, Gorden, K, et al. Low serum vitamin D concentrations in patients with schizophrenia. Isr Med Assoc J. 2012; 14, 8892.Google ScholarPubMed
26. Kjaergaard, M, Waterloo, K, Wang, CEA, et al. Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial. Br J Psychiatry. 2012; 201, 360368.CrossRefGoogle ScholarPubMed
27. Maddock, J, Berry, DJ, Geoffroy, M-C, Power, C, Hyppönen, E. Vitamin D and common mental disorders in mid-life: cross-sectional and prospective findings. Clin Nutr. 2013; 32, 758764.CrossRefGoogle ScholarPubMed
28. McGrath, JJ, Burne, TH, Féron, F, Mackay-Sim, A, Eyles, DW. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull. 2010; 36, 10731078.CrossRefGoogle ScholarPubMed
29. Jones, G, Prosser, DE, Kaufmann, M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2013; 55, 1331.CrossRefGoogle ScholarPubMed
30. Jones, G, Prosser, DE, Kaufmann, M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012; 523, 918.CrossRefGoogle ScholarPubMed
31. Eyles, DW, Smith, S, Kinobe, R, Hewison, M, McGrath, JJ. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat. 2005; 29, 2130.CrossRefGoogle ScholarPubMed
32. Jiang, P, Zhang, W-Y, Li, H-D, et al. Stress and vitamin D: altered vitamin D metabolism in both the hippocampus and myocardium of chronic unpredictable mild stress exposed rats. Psychoneuroendocrinology. 2013; 38, 20912098.CrossRefGoogle ScholarPubMed
33. Schuster, I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011; 1814, 186199.CrossRefGoogle ScholarPubMed
34. Haussler, MR, Mangelsdorf, DJ, Komm, BS, et al. Molecular biology of the vitamin D hormone. Proceedings of the 1987 Laurentian Hormone Conference, Elsevier BV, pp. 263–305, 1988.Google Scholar
35. Mangelsdorf, DJ, Thummel, C, Beato, M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83, 835839.CrossRefGoogle ScholarPubMed
36. Prüfer, K, Veenstra, TD, Jirikowski, GF, Kumar, R. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat. 1999; 16, 135145.CrossRefGoogle ScholarPubMed
37. Christakos, S, Dhawan, P, Liu, Y, Peng, X, Porta, A. New insights into the mechanisms of vitamin D action. J Cell Biochem. 2003; 88, 695705.CrossRefGoogle ScholarPubMed
38. Sequeira, VB, Rybchyn, MS, Tongkao-on, W, et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1α,25-dihydroxyvitamin D3 . Mol Endocrinol. 2012; 26, 574582.CrossRefGoogle ScholarPubMed
39. Bernd, P. The role of neurotrophins during early development. Gene Expr. 2008; 14, 241250.CrossRefGoogle ScholarPubMed
40. Barker, T, Martins, TB, Hill, HR, et al. Circulating pro-inflammatory cytokines are elevated and peak power output correlates with 25-hydroxyvitamin D in vitamin D insufficient adults. Eur J Appl Physiol. 2013; 113, 15231534.CrossRefGoogle ScholarPubMed
41. Ibi, M, Sawada, H, Nakanishi, M, et al. Protective effects of 1α,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001; 40, 761771.CrossRefGoogle Scholar
42. Favalli, G, Li, J, Belmonte-de-Abreu, P, Wong, AHC, Daskalakis, ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res. 2012; 46, 111.CrossRefGoogle ScholarPubMed
43. Wang, Y, Chiang, YH, Su, TP, et al. Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology. 2000; 39, 873880.CrossRefGoogle ScholarPubMed
44. Zhang, Y, Leung, DYM, Richers, BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012; 188, 21272135.CrossRefGoogle ScholarPubMed
45. Miller, GE, Chen, E, Parker, KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging: moving toward a model of behavioral and biological mechanisms. Psychol Bull. 2011; 137, 959997.CrossRefGoogle Scholar
46. Schwieler, L, Larsson, MK, Skogh, E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia – significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015; 40, 126133.Google ScholarPubMed
47. Kalmady, SV, Venkatasubramanian, G, Shivakumar, V, et al. Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naïve schizophrenia: evidence for differential susceptibility? PLoS ONE. 2014; 9, e96021.CrossRefGoogle ScholarPubMed
48. Yong, DEJ, Booth, P, Baruni, J, et al. Chromosome 22q11 microdeletion and congenital heart disease – a survey in a paediatric population. Eur J Pediatr. 1999; 158, 566570.CrossRefGoogle Scholar
49. Sieberer, M, Haltenhof, H, Haubitz, B, et al. Basal ganglia calcification and psychosis in 22q11.2 deletion syndrome. Eur Psychiatry. 2005; 20, 567569.CrossRefGoogle ScholarPubMed
50. Jyonouchi, S, McDonald-McGinn, DM, Bale, S, Zackai, EH, Sullivan, KE. CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features. Pediatrics. 2009; 123, e871e877.CrossRefGoogle ScholarPubMed
51. Kar, P, Ogoe, B, Poole, R, Meeking, D. Di-George syndrome presenting with hypocalcaemia in adulthood: two case reports and a review. J Clin Pathol. 2005; 58, 655657.CrossRefGoogle ScholarPubMed
52. Kapadia, CR, Kim, YE, McDonald-McGinn, DM, Zackai, EH, Katz, LEL. Parathyroid hormone reserve in 22q11.2 deletion syndrome. Genet Med. 2008; 10, 224228.CrossRefGoogle ScholarPubMed
53. Kinney, DK, Hintz, K, Shearer, EM, et al. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses. 2010; 74, 555563.CrossRefGoogle Scholar
54. McLean-Tooke, A, Spickett, GP, Gennery, AR. Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scand J Immunol. 2007; 66, 17.CrossRefGoogle ScholarPubMed
55. Taylor, S, Morris, G, Wilson, D, Davies, S, Gregory, J. Hypoparathyroidism and 22q11 deletion syndrome. Arch Dis Child. 2003; 88, 520522.CrossRefGoogle ScholarPubMed
56. Cheung, ENM, George, SR, Costain, GA, et al. Prevalence of hypocalcaemia and its associated features in 22q11.2 deletion syndrome. Clin Endocrinol. 2014; 81, 190196.CrossRefGoogle ScholarPubMed
57. Wheeler, AL, Shoback, DM. Clinical presentation of hypoparathyroidism. In Hypoparathyroidism (eds. Brandi LM, Brown ME), 2015; pp. 155–165. Springer, Milan.Google Scholar
58. Brauner, R, de Gonneville, ALH, Kindermans, C, et al. Parathyroid function and growth in 22q11.2 deletion syndrome. J Pediatr. 2003; 142, 504508.CrossRefGoogle ScholarPubMed
59. Bassett, AS, McDonald-McGinn, DM, Devriendt, K, et al. Practical guidelines for managing patients with 22q11. 2 deletion syndrome. J Pediatr. 2011; 159, 332339, e331.CrossRefGoogle ScholarPubMed
60. Cui, X, Gooch, H, Groves, NJ, et al. Vitamin D and the brain: key questions for future research. J Steroid Biochem Mol Biol. 2015; 148, 305309.CrossRefGoogle ScholarPubMed
61. Kalueff, AV, Lou, Y-R, Laaksi, I, Tuohimaa, P. Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain Res Bull. 2004; 64, 2529.CrossRefGoogle ScholarPubMed
62. Zou, J, Minasyan, A, Keisala, T, et al. Progressive hearing loss in mice with a mutated vitamin D receptor gene. Audiol Neurootol. 2008; 13, 219230.CrossRefGoogle ScholarPubMed
63. Burne, T, McGrath, J, Eyles, D, Mackaysim, A. Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res. 2005; 157, 299308.CrossRefGoogle ScholarPubMed
64. Kalueff, A, Loseva, E, Haapasalo, H, et al. Thalamic calcification in vitamin D receptor knockout mice. Neuroreport. 2006; 17, 717721.CrossRefGoogle ScholarPubMed
65. Thompson, E, Kline, E, Reeves, G, Pitts, SC, Schiffman, J. Identifying youth at risk for psychosis using the behavior assessment system for children. Schizophr Res. 2013; 151, 238244.CrossRefGoogle ScholarPubMed
66. Reynolds, CR, Kamphaus, RW. Manual for Behavior Assessment System for Children. 1992. AGS Publishing: Circle Pine, MN.Google Scholar
67. Wechsler, D. WISC-IV Technical and Interpretive Manual. 2003. The Psychological Corporation: San Antonio, TX.Google Scholar
68. Mowry, B, Holmans, P, Pulver, A, et al. Multicenter linkage study of schizophrenia loci on chromosome 22q. Mol Psychiatry. 2004; 9, 784795.CrossRefGoogle Scholar
69. Goodman, B, Rutberg, J, Lin, W, Pulver, A, Thomas, G, Geraghty, M. Hyperprolinaemia in patients with deletion (22)(q11. 2) syndrome. J Inherit Metab Dis. 2000; 23, 847848.CrossRefGoogle ScholarPubMed
70. Clelland, CL, Read, LL, Baraldi, AN, et al. Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome. Schizophr Res. 2011; 131, 139145.CrossRefGoogle Scholar
71. Clelland, JD, Read, LL, Drouet, V, et al. Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of association. Schizophr Res. 2014; 156, 1522.CrossRefGoogle ScholarPubMed
72. Roussos, P, Giakoumaki, SG, Bitsios, P. A risk PRODH haplotype affects sensorimotor gating, memory, schizotypy, and anxiety in healthy male subjects. Biol Psychiatry. 2009; 65, 10631070.CrossRefGoogle Scholar
73. Schneider, M, Debbané, M, Bassett, AS, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. Am J Psychiatry. 2014; 171, 627639.CrossRefGoogle ScholarPubMed
74. Shivakumar, V, Kalmady, SV, Amaresha, AC, et al. Serum vitamin D and hippocampal gray matter volume in schizophrenia. Psychiatry Res. 2015; 233, 175179.CrossRefGoogle Scholar
75. Debbané, M, Schaer, M, Farhoumand, R, Glaser, B, Eliez, S. Hippocampal volume reduction in 22q11.2 deletion syndrome. Neuropsychologia. 2006; 44, 23602365.CrossRefGoogle ScholarPubMed
76. DeBoer, T, Wu, Z, Lee, A, Simon, TJ. Hippocampal volume reduction in children with chromosome 22q11.2 deletion syndrome is associated with cognitive impairment. Behav Brain Funct. 2007; 3, 54.CrossRefGoogle ScholarPubMed
77. Jiang, P, Xue, Y, Li, H-D, et al. Dysregulation of vitamin D metabolism in the brain and myocardium of rats following prolonged exposure to dexamethasone. Psychopharmacology. 2014; 231, 34453451.CrossRefGoogle ScholarPubMed
78. Jiang, P, Zhang, L, Zhu, W, et al. Chronic stress causes neuroendocrine-immune disturbances without affecting renal vitamin D metabolism in rats. J Endocrinol Invest. 2014; 37, 11091116. : 10.1007/s40618-014-0191-5.CrossRefGoogle ScholarPubMed
79. Jorde, R, Mathiesen, EB, Rogne, S, et al. Vitamin D and cognitive function: the Tromsø Study. J Neurol Sci. 2015; 355, 155161.CrossRefGoogle ScholarPubMed
80. Van der Schaft, J, Koek, H, Dijkstra, E, Verhaar, H, van der Schouw, Y, Emmelot-Vonk, M. The association between vitamin D and cognition: a systematic review. Ageing Res Rev. 2013; 12, 10131023.CrossRefGoogle ScholarPubMed
81. Wehr, H, Bednarska-Makaruk, M. Vitamin D and cognition. Adv Psychiatry Neurol. 2016; 25, 4953.Google Scholar
82. Sigwalt, AR, Budde, H, Helmich, I, et al. Molecular aspects involved in swimming exercise training reducing anhedonia in a rat model of depression. Neuroscience. 2011; 192, 661674.CrossRefGoogle Scholar
83. Obradovic, D, Gronemeyer, H, Lutz, B, Rein, T. Cross-talk of vitamin D and glucocorticoids in hippocampal cells. J Neurochem. 2006; 96, 500509.CrossRefGoogle ScholarPubMed
84. Ansari, NN, Spilioti, E, Kalotychou, V, et al. Vitamin D decreases in vitro glucocorticoid sensitivity via down regulation of glucocorticoid receptor expression. Endocr Abstr. 2015; 37 OC5.2. Google Scholar
85. Diamond, DM, Bennett, MC, Fleshner, M, Rose, GM. Inverted-U relationship between the level of peripheral corticosterone and the magnitude of hippocampal primed burst potentiation. Hippocampus. 1992; 2, 421430.CrossRefGoogle ScholarPubMed
86. Joëls, M. Corticosteroid effects in the brain: U-shape it. Trends Pharmacol Sci. 2006; 27, 244250.CrossRefGoogle Scholar
87. Walker, E, Mittal, V, Tessner, K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol. 2008; 4, 189216.CrossRefGoogle ScholarPubMed
88. Corcoran, CM, Smith, C, McLaughlin, D, et al. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res. 2012; 135, 170174.CrossRefGoogle ScholarPubMed
89. Karanikas, E, Antoniadis, D, Garyfallos, GD. The role of cortisol in first episode of psychosis: a systematic review. Curr Psychiatry Rep. 2014; 16, 503.CrossRefGoogle ScholarPubMed
90. Labad, J, Stojanovic-Pérez, A, Montalvo, I, et al. Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin. J Psychiatr Res. 2015; 60, 163169.CrossRefGoogle ScholarPubMed
91. Karanikas, E, Garyfallos, G. Role of cortisol in patients at risk for psychosis mental state and psychopathological correlates: a systematic review. Psychiatry Clin Neurosci. 2015; 69, 268282.CrossRefGoogle Scholar
92. Pruessner, M, Béchard-Evans, L, Boekestyn, L, et al. Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. Schizophr Res. 2013; 146, 7986.CrossRefGoogle ScholarPubMed
93. Frighi, V, Morovat, A, Stephenson, MT, et al. Vitamin D deficiency in patients with intellectual disabilities: prevalence, risk factors and management strategies. Br J Psychiatry. 2014; 205, 458464.CrossRefGoogle ScholarPubMed
94. Grant, WB, Wimalawansa, SJ, Holick, MF, et al. Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities. Nutrients. 2015; 7, 15381564.CrossRefGoogle ScholarPubMed
95. Bicíková, M, Dusková, M, Vítku, J, et al. Vitamin D in anxiety and affective disorders. Physiol Res. 2015; 64, S101S103.Google ScholarPubMed
96. Black, LJ, Jacoby, P, Allen, KL, et al. Low vitamin D levels are associated with symptoms of depression in young adult males. Aust N Z J Psychiatry. 2014; 48, 464471.CrossRefGoogle Scholar
97. Wu, C, Ren, W, Cheng, J, et al. Association between serum levels of vitamin D and the risk of post-stroke anxiety. Medicine. 2016; 95, e3566.CrossRefGoogle ScholarPubMed
98. Bertone-Johnson, ER. Vitamin D and the occurrence of depression: causal association or circumstantial evidence? Nutr Rev. 2009; 67, 481492.CrossRefGoogle Scholar
99. Holick, MF, Binkley, NC, Bischoff-Ferrari, HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96, 19111930.CrossRefGoogle ScholarPubMed
100. Moyad, MA. Heart Health = Urologic Health and Heart Unhealthy = Urologic Unhealthy: rapid review of lifestyle changes and dietary supplements. Urol Clin North Am. 2011; 38, 359367.CrossRefGoogle ScholarPubMed
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Vitamin D deficiency, behavioral atypicality, anxiety and depression in children with chromosome 22q11.2 deletion syndrome
Available formats

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Vitamin D deficiency, behavioral atypicality, anxiety and depression in children with chromosome 22q11.2 deletion syndrome
Available formats

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Vitamin D deficiency, behavioral atypicality, anxiety and depression in children with chromosome 22q11.2 deletion syndrome
Available formats

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *